173 related articles for article (PubMed ID: 37657228)
1. Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM; Engelhardt EG; Gerritsma MA; Sondermeijer CMT; Verschuur E; Houtzager J; Griffioen R; Retèl V; Bijker N; Mann RM; van Duijnhoven F; Wesseling J; Bleiker EMA;
Eur J Cancer; 2023 Oct; 192():113276. PubMed ID: 37657228
[TBL] [Abstract][Full Text] [Related]
2. How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a randomised comparison within a national community survey.
McCaffery K; Nickel B; Moynihan R; Hersch J; Teixeira-Pinto A; Irwig L; Barratt A
BMJ Open; 2015 Nov; 5(11):e008094. PubMed ID: 26525720
[TBL] [Abstract][Full Text] [Related]
3. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
5. How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study.
Nickel B; Barratt A; Hersch J; Moynihan R; Irwig L; McCaffery K
Breast; 2015 Oct; 24(5):673-9. PubMed ID: 26376460
[TBL] [Abstract][Full Text] [Related]
6. Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study.
Nickel B; McCaffery K; Houssami N; Jansen J; Saunders C; Spillane A; Rutherford C; Dixon A; Barratt A; Stuart K; Robertson G; Hersch J
Breast; 2020 Dec; 54():99-105. PubMed ID: 32971350
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
8. Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO; Smith BL; Lehman CD; Vijapura CA; Pinnamaneni N; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4459-4465. PubMed ID: 32418079
[TBL] [Abstract][Full Text] [Related]
9. The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.
Alaeikhanehshir S; Engelhardt EG; van Duijnhoven FH; van Seijen M; Bhairosing PA; Pinto D; Collyar D; Sawyer E; Hwang SE; Thompson AM; Wesseling J; Lips EH; Schmidt MK;
Breast; 2020 Apr; 50():95-103. PubMed ID: 32120064
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Estimating the magnitude of clinical benefit of local therapy in patients with DCIS.
Hwang ES; Malek V
Breast; 2019 Nov; 48 Suppl 1():S34-S38. PubMed ID: 31839157
[TBL] [Abstract][Full Text] [Related]
12. Non-surgical treatment for ductal carcinoma in situ of the breasts - a prospective study on patient's perspective.
Co M; Lee A; Kwong A
Cancer Treat Res Commun; 2021; 26():100241. PubMed ID: 33340904
[TBL] [Abstract][Full Text] [Related]
13. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
14. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
15. Is DCIS breast cancer, and how do I treat it?
Bijker N; Donker M; Wesseling J; den Heeten GJ; Rutgers EJ
Curr Treat Options Oncol; 2013 Mar; 14(1):75-87. PubMed ID: 23239193
[TBL] [Abstract][Full Text] [Related]
16. Treatment decision-making in ductal carcinoma in situ: A mixed methods systematic review of women's experiences and information needs.
Rutherford C; Mercieca-Bebber R; Butow P; Wu JL; King MT
Patient Educ Couns; 2017 Sep; 100(9):1654-1666. PubMed ID: 28442156
[TBL] [Abstract][Full Text] [Related]
17. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
18. Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.
Nickel B; McCaffery K; Jansen J; Barratt A; Houssami N; Saunders C; Spillane A; Rutherford C; Stuart K; Robertson G; Dixon A; Hersch J
PLoS One; 2023; 18(7):e0288972. PubMed ID: 37478123
[TBL] [Abstract][Full Text] [Related]
19. Analysis of active surveillance as a treatment modality in ductal carcinoma in situ.
Fan B; Pardo JA; Alapati A; Hopewood P; Mohammad Virk Z; James TA
Breast J; 2020 Jun; 26(6):1221-1226. PubMed ID: 31925857
[TBL] [Abstract][Full Text] [Related]
20. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
